Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-cash Items (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Non-cash Items for 4 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-cash Items fell 85.56% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Sep 2025, down 85.56%, and an annual FY2024 reading of $27000.0, changed N/A over the prior year.
  • Non-cash Items was $2.7 million for Q3 2025 at Atara Biotherapeutics, up from $400000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $47.4 million in Q1 2022 and bottomed at $27000.0 in Q4 2024.
  • Average Non-cash Items over 4 years is $17.3 million, with a median of $11.5 million recorded in 2024.
  • The sharpest move saw Non-cash Items surged 62972.78% in 2023, then crashed 95.7% in 2025.
  • Year by year, Non-cash Items stood at $42000.0 in 2022, then surged by 55614.29% to $23.4 million in 2023, then tumbled by 99.88% to $27000.0 in 2024, then surged by 9900.0% to $2.7 million in 2025.
  • Business Quant data shows Non-cash Items for ATRA at $2.7 million in Q3 2025, $400000.0 in Q2 2025, and $27000.0 in Q4 2024.